Please login to the form below

Not currently logged in
Email:
Password:

German pharma market to edge up to $65bn by 2020

Report finds that laws designed to curb drug prices will also slow down growth

German flagGermany's pharmaceutical market will only 'crawl' forward for the rest of the decade as the country looks to reduce spend on new medicines, according to research and consulting firm GlobalData.

While Germany is the leading pharma market in Europe, valued at $58.6bn last year, the sector will expand at a modest Compound Annual Growth Rate (CAGR) of 1.7% to reach an estimated $65bn by 2020.

Germany is a mature market with high healthcare expenditure and pharmaceutical production - but it is the cost-saving government policies that remain the largest barrier to future growth.

In 2011, the German government initiated a law on the reorganisation of the pharmaceutical market, Arzneimittelmarkt-Neuordnungsgesetz (AMNOG), with the aim of slowing down the growing drug expenditure within the public health sector. This law introduced measures that have not been welcomed by most drug manufacturers.

Joshua Owide, GlobalData's director of healthcare industry dynamics, explains: “Before the enactment of AMNOG in Germany, there were far fewer limitations to the pricing of new or patented products, which was itself a key driver of rising drug expenditure.

“AMNOG features an early benefit assessment for newly registered medicinal products, whereby drugs with no additional benefit are placed on the Reference Pricing system, which fixes a maximum reimbursement limit for groups of comparable treatments. For drugs with added benefits, prices can be negotiated with their manufacturers.”

GlobalData's report notes that these measures are further exacerbated by government-imposed price freezes and reductions on pharmaceuticals, a large market for generic products and the exclusion of several drug categories by Statutory Health Insurance (SHI).

Owide continues: “Patients are often unwilling to opt for drugs that are not reimbursed by SHI funds, which impacts the market for those products.

“Furthermore, according to Federal Health Reporting, the German generic market is the largest in the EU, accounting for approximately 73.5% by volume and 33.1% by value of Germany's total pharmaceutical sales in 2013. This tendency to favour generics may restrict future sales of patented drugs.”

Article by
Ben Adams

27th March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics